ArcticZymes Technologies - Regulatory Filings 2014

Release of early results from ongoing evaluation study with Smith & Nephew in UK presented at the annual health care conference "Wounds UK".

Biotec Pharmacon has received results presented as posters from two of the

clinical centers in the Smith & Nephew evaluation trial on Woulgan® Biogel. The

posters were presented at the health care conference in Harrogate, London called

"Wounds UK".

The City Health Care Partnership in Hull and Croydon Health Services in London

presented results from 16 patients with leg ulcers and 11 patients with diabetic

foot ulcers, all treated with Woulgan® Biogel. The clinicians observing

treatment of the 16 leg ulcer patients reported that all ulcers experienced

improved healing during the treatment period and that patients experienced less

pain and improved comfort compared to previous therapies. Patient concordance

with the treatment was surprisingly high. 93% of patients assessed the treatment

effect as "very good", whereas the remaining 7% assessed it as "good".

For the 11 diabetic foot ulcer patients, it was reported that Woulgan® Biogel

was easily applied to the ulcers saving clinician treatment time, had no side

effects and improved the healing of some of these chronic ulcers.

The posters can be found at www.biotec.no

For further information, please contact:

CEO Svein W. F. Lien, tel +47 922 89 323

CSO Rolf E. Engstad, tel +47 959 41 542

About Biotec BetaGlucans and Woulgan® Biogel

Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec

BetaGlucans develop and manufactures novel immunomodulating products. Newly

developed Woulgan® Biogel for use in wound healing, contains the company's

proprietary substance SBG®. Woulgan® Biogel is a sterile, homogen, thick gel

containing water, glycerol, 2% SBG, and carboxymethylcellulose. The product does

not contain any preservatives. The Woulgan® Biogel is a single-patient primary

dressing for one-time use on skin wounds including diabetic ulcers, bedsores,

leg ulcers, transplantation wounds, post-surgery wounds, trauma wounds, first-

and second-degree burns, abrasions, and cuts. The company has entered into an

agreement with world leaders Smith & Nephew for distribution of Woulgan® Biogel

after a market evaluation period based on regular clinical use.

More information about Woulgan® Biogel is available on the company's homepage

AI assistant